Sumitomo Mitsui Trust Holdings, Inc. Cellectis S.A. Transaction History

Sumitomo Mitsui Trust Holdings, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 27, 2022	SELL	$3.45 - $8.77 $2.17 Million - $5.51 Million	-627,910 Closed	0 $0
Q4 2021 Feb 02, 2022	SELL	$8.01 - $12.84 $548,564 - $879,347	-68,485 Reduced 9.83%	627,910 $5.1 Million
Q3 2021 Oct 25, 2021	SELL	$11.94 - $16.09 $1.18 Million - $1.58 Million	-98,488 Reduced 12.39%	696,395 $8.78 Million
Q2 2021 Aug 02, 2021	SELL	$14.36 - $20.93 $1.37 Million - $2 Million	-95,628 Reduced 10.74%	794,883 $12.3 Million
Q1 2021 Apr 30, 2021	BUY	$18.19 - $33.25 $2.12 Million - $3.88 Million	116,723 Added 15.08%	890,511 $18 Million
Q4 2020 Feb 05, 2021	BUY	$15.87 - $31.64 $1.8 Million - $3.6 Million	113,700 Added 17.22%	773,788 $20.9 Million
Q3 2020 Oct 30, 2020	SELL	$15.7 - $20.84 $1.21 Million - $1.6 Million	-76,762 Reduced 10.42%	660,088 $12.2 Million
Q2 2020 Jul 27, 2020	SELL	$8.21 - $21.02 $4.55 Million - $11.6 Million	-554,223 Reduced 42.93%	736,850 $13.1 Million
Q1 2020 Apr 27, 2020	BUY	$7.81 - $18.82 $93,142 - $224,447	11,926 Added 0.93%	1,291,073 $11.9 Million
Q4 2019 Jan 31, 2020	SELL	$9.73 - $19.31 $341,990 - $678,707	-35,148 Reduced 2.67%	1,279,147 $21.9 Million
Q3 2019 Oct 31, 2019	BUY	$10.15 - $16.89 $1.06 Million - $1.76 Million	104,276 Added 8.62%	1,314,295 $13.7 Million
Q2 2019 Jul 29, 2019	BUY	$14.6 - $20.6 $5.74 Million - $8.09 Million	392,841 Added 48.07%	1,210,019 $18.9 Million
Q1 2019 May 08, 2019	BUY	$15.53 - $19.75 $12.7 Million - $16.1 Million	817,178 New	817,178 $15 Million

11.2M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $88.3M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Sumitomo Mitsui Trust Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Sumitomo Mitsui Trust Holdings, Inc. with notifications on news.